Key facts
- This page summarizes Douglas E. Onsi's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Jan 2024, 20:37.
Douglas E. Onsi - 26 Jan 2024 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)
- Reporting relationship
- CEO,CFO,Pres.,GC,Treas.,&Sec., Director
- Issuer ticker
- LPTX
- Reported as of
- 26 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2024, 20:37:21 UTC
- Prior SEC filing
- 25 Aug 2023
- Next SEC filing
- 31 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas E. Onsi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Onsi filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 30 Jan 2024.
Change
- Previous filing in this sequence was filed on 25 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LPTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,500
- Change %
- +11%
- Price
- Shares after
- 73,646
- Date
- 26 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
LPTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 414,480
- Date
- 26 Jan 2024
- Ownership
- By HealthCare Ventures IX, L.P.
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LPTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -7,500
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 26 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Restricted Stock Units convert into common stock on a one-for-one basis.
Footnote F2
The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.
Footnote F3
The reporting person is a Managing Director of HealthCare Partners IX, LLC which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HealthCare Ventures IX, L.P. The reporting person beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein.
Footnote F4
On January 26, 2021, the reporting person was granted 7,500 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit.